Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

English is OK for most labels, says Norwegian expert:

This article was originally published in Clinica

Executive Summary

A Norwegian official has rushed to defend his country's language requirements for CE-marked medical devices. They are not, says Jacob Nordan, as onerous as was suggested recently (see Clinica No 775, p 6). Manufacturers may sell products in any language as long as it is stated on the labelling; English is understood by most healthcare professionals. Norwegian must be used in the instructions when the user is the patient or a non-professional user, explained Mr Nordan, a medical devices expert at the Board of Health.

You may also be interested in...



US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market

Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT086470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel